Compare SAM & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAM | TNGX |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 1996 | 2020 |
| Metric | SAM | TNGX |
|---|---|---|
| Price | $163.00 | $21.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $233.70 | $21.78 |
| AVG Volume (30 Days) | 265.7K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.45 | 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,964,994,000.00 | $62,384,000.00 |
| Revenue This Year | $1.02 | N/A |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $162.31 | $3.12 |
| 52 Week High | $264.46 | $28.41 |
| Indicator | SAM | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 25.73 | 47.47 |
| Support Level | N/A | $20.05 |
| Resistance Level | $228.42 | $22.01 |
| Average True Range (ATR) | 6.96 | 1.71 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 3.66 | 30.36 |
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.